Key terms

About AUTL

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest AUTL news

Yesterday 1:40pm ET Analysts Are Bullish on Top Healthcare Stocks: Autolus Therapeutics (AUTL), Citius Pharmaceuticals (CTXR) Yesterday 8:42am ET Autolus Therapeutics Shares Q1 Results and Corporate Update Yesterday 7:05am ET Options Volatility and Implied Earnings Moves Today, May 17, 2024 Yesterday 7:02am ET Autolus Therapeutics reports Q1 EPS (24c), consensus (5c) May 13 9:38am ET Autolus files to delay quarterly report, cancels earnings call May 13 7:32am ET Autolus Therapeutics Announces Q1 2024 Financial Update May 13 7:19am ET Autolus Therapeutics announces delay to Q1 earnings release, conference call Apr 12 6:06am ET Buy Rating on Autolus Therapeutics: Innovative Cancer Treatments and Strategic Leadership Drive Positive Outlook Apr 02 7:16am ET Autolus Therapeutics announces acceptance of MAA by EMA for obe-cel Apr 01 7:22am ET Autolus Therapeutics Announces Board Leadership Changes Apr 01 7:19am ET Autolus chairman John Johnson steps down, Mike Bonney succeeds Mar 28 4:22pm ET Autolus files to sell 33.33M American Depositary Shares for holders Mar 25 8:41am ET Aveo Oncology appoints Edgar Braendle as CMO Mar 18 9:22am ET Autolus Therapeutics price target raised to $10 from $9 at Truist Mar 14 1:40pm ET Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Coherus Biosciences (CHRS) and Autolus Therapeutics (AUTL) Mar 14 12:42pm ET Autolus Therapeutics Announces Annual Results and CDO Resignation Mar 12 7:28am ET Autolus Therapeutics receives MHRA certification for Nucleus site Mar 11 7:08am ET Autolus Therapeutics announces publication in Blood Cancer Journal Feb 22 7:21am ET Autolus Therapeutics announces publication in Nature Communications

No recent press releases are available for AUTL

AUTL Financials

1-year income & revenue

Key terms

AUTL Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

AUTL Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms